RxDoctor Payments Data

Farris Johnson, MD

Family Medicine · Athens, GANPI 1487682787

Payments from drug & device makers

$5,226in general payments, 2019–2025

Across 122 payments — averaging $42.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Novo Nordisk$648
  • AbbVie$631
  • AstraZeneca$474
  • Sanofi-aventis U.S. LLC$439
  • Pfizer$120
  • plus $311 from 7 others

What the payments were for

  • Speaking & faculty fees$2,53048%
  • Travel & lodging$491%
  • Food & beverage$2,63550%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,226 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$107,846
Medicare patients
228
Services billed
4,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide190$282,841
TrulicityDulaglutide39$93,058
MounjaroTirzepatide48$88,180
JardianceEmpagliflozin89$84,393
RybelsusSemaglutide31$60,752
XareltoRivaroxaban52$56,546
LinzessLinaclotide40$54,408
KerendiaFinerenone41$48,442
Invega SustennaPaliperidone Palmitate13$44,496
EliquisApixaban38$40,640
FarxigaDapagliflozin Propanediol37$31,567
VraylarCariprazine Hcl16$31,317
JanumetSitagliptin Phos/Metformin Hcl28$27,279
JanuviaSitagliptin Phosphate20$25,215
Tresiba Flextouch U-200Insulin Degludec34$22,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$648$343,592221 claims
Lilly USA, LLCTrulicity, Mounjaro$52$181,23987 claims
AbbVieLinzess, Vraylar, Synthroid$631$90,397108 claims
Boehringer IngelheimJardiance$34$84,39389 claims
BayerKerendia$52$48,44241 claims
AstraZenecaFarxiga, Breztri Aerosphere$474$44,09857 claims
PfizerEliquis$120$40,64038 claims
GSKTrelegy Ellipta$25$17,01425 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$439$14,10514 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$2,604$9,32324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →